Advanced chemical analytics,
in your browser.

Ibogaine — naturally occurring indole alkaloid from the West African shrub Tabernanthe iboga, long used outside the US to interrupt opioid use disorder in a single multi-day dose. Stanford's 30-veteran study (Cherian et al., Nature Medicine 2024) paired ibogaine with magnesium to mitigate QT prolongation and reported one-month reductions of 88% in PTSD, 87% in depression, and 81% in anxiety symptoms in special-operations veterans with traumatic brain injury. On 18 April 2026, with Joe Rogan standing behind him in the Oval Office, President Trump signed "Accelerating Medical Treatments for Serious Mental Illness" — directing HHS to channel at least $50M to states developing psychedelic programs and instructing the FDA + DEA to open a Right to Try pathway for ibogaine. Rogan said he had texted the president about the molecule and got back "Sounds great! Do you want FDA approval? Let's do it!" — the policy turn the field had been waiting on for two decades.

Psilocybin — prodrug of psilocin, active in psilocybe mushrooms and the leading psychedelic candidate for FDA approval. Compass Pathways hit its primary endpoint in two Phase-3 trials of synthetic COMP360 for treatment-resistant depression: COMP005 (June 2025, single 25 mg dose, MADRS -3.6 vs placebo, p<0.001) and COMP006 (February 2026, two 25 mg doses, -3.8 vs 1 mg active comparator at Week 6, 39% achieving meaningful response). In April 2026 the FDA granted COMP360 a rolling NDA review and a Commissioner's National Priority Voucher — a 1-2 month review-clock pathway that could deliver the first FDA-approved psychedelic by 2027.

Methylone (TSND-201) - β-keto analog of MDMA differing only by a single ketone insertion that eliminates 5-HT2A activity (so non-hallucinogenic) while preserving rapid-onset monoamine release. Transcend Therapeutics' Phase-2 IMPACT-1 trial in 65 severe-PTSD participants hit its primary endpoint with a placebo-adjusted CAPS-5 reduction of -9.64 at Day 64. The FDA granted Breakthrough Therapy designation in July 2025; on 27 April 2026 - nine days after Trump's psychedelic executive order - the agency awarded Transcend a National Priority Voucher, putting methylone on a 1-2 month review-clock pathway and ahead of MDMA itself in the regulatory queue. Otsuka Pharmaceutical announced its acquisition of Transcend the same year.

Midomafetamine (MDMA) - submitted to the FDA in 2024 as the first psychedelic to reach a PDUFA decision in modern history. The agency issued a Complete Response Letter on 9 August 2024 requesting an additional Phase-3 trial despite Phase-3 data showing 67% of MDMA-arm participants no longer meeting PTSD diagnostic criteria (vs 32% on placebo). Sponsor Lykos Therapeutics restructured by ~75% and the FDA released the full CRL in September 2025. When the Trump administration's 18 April 2026 psychedelic executive order paired with FDA priority vouchers, MDMA was conspicuously not among the three picks - vouchers went instead to two psilocybin programs and Transcend Therapeutics' methylone, leaving MDMA-AT in regulatory limbo while the rest of the field accelerates.

Semaglutide - long-acting GLP-1 receptor agonist (Ozempic / Wegovy / Rybelsus) that reshaped weight management and type-2 diabetes care. Pictured is the lipid-modified Lys26 side-chain - the C18 fatty diacid plus γ-Glu/OEG2 spacer that gives semaglutide its multi-day half-life via albumin binding. On 28 January 2025 the FDA approved an additional Ozempic indication to reduce kidney-disease progression and cardiovascular death (FLOW: 24% RR reduction). In early 2026 the FDA cleared the Wegovy oral tablet (OASIS-4 Phase-3: 16.6% mean weight loss at 64 weeks vs 2.7% on placebo) - the first oral GLP-1 for weight loss and Novo Nordisk's answer to needle-averse patients and the pill-based competitors now entering the class.

The world's most-consumed psychoactive compound - a methylxanthine adenosine-receptor antagonist found in coffee, tea, and cocoa. Zhang et al. (JAMA, 2026) followed 130,000 Nurses' Health Study and Health Professionals Follow-Up participants for up to 43 years and found 2-3 cups/day of caffeinated coffee was associated with an 18% lower dementia risk and slower cognitive decline; the effect survived adjustment for the APOE4 risk allele, while decaffeinated coffee showed no equivalent benefit - pointing at caffeine itself as the active factor.

Acetylsalicylic acid - the first mass-produced synthetic drug (Bayer, 1899) and an irreversible covalent inhibitor of cyclooxygenase via acetylation of COX-1 Ser530. After a century as the canonical analgesic, low-dose aspirin remains a workhorse of secondary cardiovascular prevention; primary-prevention guidance has tightened. A March 2026 meta-analysis from West China Hospital of Sichuan University (10 RCTs, 124,837 participants) found no meaningful reduction in colorectal cancer or precursor lesions among average-risk adults, reinforcing the USPSTF 2022 reversal and the broader shift toward precision prevention rather than population-wide prophylaxis.